TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 GeneticVariation group BEFREE Recommendations did not agree on the safety of using disease-modifying antirheumatic drugs in RA patients with cancer, except for the contraindication of tumor necrosis factor inhibitors in patients at risk for lymphoma. 30821928 2020
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Recently, the tumor necrosis factor receptor superfamily cluster of differentiation 30 (CD30) has been thought to be implicated in malignant cells in organs affected by Hodgikin lymphoma or in a prognostic marker of diffuse large B cell lymphoma. 31335688 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Only four studies found a significant association of anti-TNF drug with lymphoma or groups of cancers including lymphoma. 30941038 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 GeneticVariation group BEFREE The tumor necrosis factor receptor superfamily member HVEM is one of the most frequently mutated surface proteins in germinal center (GC)-derived B cell lymphomas. 31204070 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 GeneticVariation group BEFREE TNFα antagonists may also be associated with an increased risk of lymphoma, especially when combined with thiopurines. 31322018 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 GeneticVariation group BEFREE Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. 29762681 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Thus, spreading of ADAM10 activity due to ExoV can result in the release of cytokines, like TNFα, a lymphoma growth factor, or soluble molecules, like sMICA or sCD30, that potentially interfere with host immune surveillance or immunotherapy. 29721369 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE This case suggests a potential relationship between immunosuppression with anti-TNFα medication, and increased risk for lymphoma, especially in patients with underlying rheumatologic disorders and especially in patients with suspected chronic refractory uveitis. 29954352 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. 29114832 2017
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Thus, even if meta-analysis of randomized controlled trials and of registries have not demonstrated to date an increased risk of lymphoma with anti-TNF, cautious must be pursued concerning this possible side effect in patients with long-term anti-TNF exposure. 28214146 2017
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Studies using better measures of adiposity are needed to further investigate the interactions between obesity and TNF-308G>A in the pathogenesis of lymphoma. 25962811 2015
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Doxorubicin resistant Dalton's lymphoma is susceptible to dendritic cell derived TNF-α upon stimulation with the STAT3 inhibitor cucurbitacin-I, which downregulates STAT3 and other survival molecules. 26255115 2015
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 AlteredExpression group BEFREE B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells. 24206092 2014
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin's lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rituximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by Vδ2 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-β and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobisphosphonate-treated mesenchymal stromal cells drive Vδ2 T-lymphocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-α and interferon-γ. 24162786 2014
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. 23306613 2013
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. 22830613 2013
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 AlteredExpression group BEFREE The soluble form of CD30 (sCD30), a member of tumor necrosis factor receptor superfamily, has been used as a marker of disease activity in various lymphomas. 21181928 2011
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 GeneticVariation group BEFREE Evidence for lymphoma developing as a result of treatment with methotrexate or Tumour Necrosis Factor Antagonists for autoimmune entities will also be reviewed. 18456377 2008
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 GeneticVariation group BEFREE As not all the patients with infection or lymphoma have secondary HLH, we investigated the relationship between susceptibility to secondary HLH and TNF-alpha promoter polymorphisms to identify genetic factors of secondary HLH. 17166738 2006
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Similarly, there was no increased rate of TNFalpha-308A in all the lymphomas studied, irrespective of lineage. 17071494 2006
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 AlteredExpression group BEFREE Furthermore, similar TTP expression in both groups correlated with an identical decay rate of TNF mRNA, which excludes this pathway for the higher LPS-induced TNF mRNA levels in PBC from lymphoma patients. 11956026 2002
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 AlteredExpression group BEFREE Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas. 11567226 2001
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 AlteredExpression group BEFREE In contrast, the relative TNF mRNA amounts were significantly higher in lymphoma patients at 30 minutes (median 27.75 vs. 16.00; Mann-Whitney U-test p < 0.05), at 4 hours (52.00 vs. 31.00; p < 0.05), and at 24 hours (19.50 vs. 9.00; p < 0.05). 11274761 2001
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE Our analysis of a series of AIDS lymphomas revealed that IFN-alpha selectively induced very high levels of the Death Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas little or no induction was observed in primary EBV+ AIDS lymphomas and EBV-Burkitt's lines. 11704827 2001
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.100 Biomarker group BEFREE We show here that murine TNF fused with CNGRC peptide (NGR-TNF), an aminopeptidase N (CD13) ligand that targets activated blood vessels in tumors, is 12-15 times more efficient than murine TNF in decreasing the tumor burden in lymphoma and melanoma animal models, whereas its toxicity is similar. 11062439 2000